Retinoblastoma vulnerability to combined
Apoptosis
Cell cycle
Dhodh
Genome alteration
Uridine uptake
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
15 Jan 2024
15 Jan 2024
Historique:
received:
12
05
2023
revised:
05
12
2023
accepted:
13
12
2023
medline:
9
2
2024
pubmed:
9
2
2024
entrez:
9
2
2024
Statut:
epublish
Résumé
Retinoblastoma is an eye cancer that commonly affects young children. Despite significant advances, current treatments cause side effects even when administered locally, and patients may still have to undergo enucleation. This is particularly disheartening in cases of bilateral retinoblastoma. Hence, there is an urgent need for novel therapeutic strategies. Inhibitors of the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in the
Identifiants
pubmed: 38332874
doi: 10.1016/j.heliyon.2023.e23831
pii: S2405-8440(23)11039-5
pmc: PMC10851301
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e23831Informations de copyright
© 2023 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:S.L. is an inventor of patent no. WO/2017/077,280 on a DHODH inhibitor class not used in this study and owns stocks in Genase Therapeutics BV.